Premium
Activity and safety of combined rituximab with chlorambucil in patients with mantle cell lymphoma
Author(s) -
Bauwens Deborah,
Maerevoet Marie,
Michaux Lucienne,
Théate Ivan,
Hagemeijer Anne,
Stul Michel,
Danse Etienne,
Costantini Sabrina,
Vannuffel Pascal,
Straetmans Nicole,
Vekemans MarieChristiane,
Deneys Véronique,
Ferrant Augustin,
Van Den Neste Eric
Publication year - 2005
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2005.05777.x
Subject(s) - medicine , chlorambucil , mantle cell lymphoma , rituximab , neutropenia , autologous stem cell transplantation , gastroenterology , fludarabine , transplantation , oncology , surgery , lymphoma , complete remission , chemotherapy , cyclophosphamide
Summary We evaluated the combination of rituximab with chlorambucil in patients with mantle cell lymphoma (MCL) not eligible for aggressive therapy. Fourteen patients (male/female: 9/5) were included (two newly diagnosed, 12 relapsed/refractory). The toxicities were neutropenia, thrombopenia and infection. Nine (64%) patients responded; five (36%) achieved complete remission and four (29%) achieved partial remission. The median progression‐free survival for responders was 26 months (95% CI, 4–48). Marrow polymerase chain reaction negativity was attained in seven responders. These results suggest that this schedule may have notable antitumour activity in patients with MCL, including patients in relapse after autologous stem cell transplantation.